Eloxx Adds Kalydeco to Ongoing Phase 2 Program Testing ELX-02
Eloxx Pharmaceuticals has announced that it’s now added the approved cystic fibrosis (CF) therapy Kalydeco (ivacaftor) to its global Phase 2 clinical program for ELX-02. Ongoing ELX-02 Phase 2 clinical trials, launched in 2019 with four treatment…